Physician profile
Daniel Morganstern
NPI 1003986852
$9,699.76
in general payments reported to CMS, 2019-2025
43 companies · $1,027 in 2025
The $1,027 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,302 · 2020: $758 · 2021: $574 · 2022: $241 · 2023: $2,493 · 2024: $1,304 · 2025: $1,027.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,363 · Long Term Medical Supply Or Device Loan: $2,196 · Food and Beverage: $266.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,362.50 |
| Long Term Medical Supply Or Device Loan | $2,196.36 |
| Food and Beverage | $265.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $5,214.61 | 2019-2025 | Kisqali |
| Puma Biotechnology, INC. | $1,160.91 | 2019-2021 | |
| Pfizer INC. | $423.33 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $273.81 | 2019-2020 | |
| Genentech USA, INC. | $235.51 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $206.25 | 2019-2021 | |
| Lilly USA, LLC | $198.04 | 2019-2021 | |
| Ge Healthcare | $183.91 | 2021-2024 | |
| Merck Sharp & Dohme LLC | $159.25 | 2019-2025 | Keytruda, Keytruda Qlex |
| Celgene Corporation | $151.24 | 2019-2021 | |
| Astellas Pharma US INC | $141.18 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $140.27 | 2019-2020 | |
| Epizyme, INC. | $100.68 | 2020-2021 | |
| Gilead Sciences, INC. | $99.15 | 2021-2022 | |
| Genzyme Corporation | $75.57 | 2019-2021 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Morganstern listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.